Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Population Pharmacokinetics for Gentamicin in Korean and Caucasian Appendicitis Patients Using Nonparametric Expected Maximum (NPEM) Algorithm

한국인과 코카시안 충수돌기염 환자에서 비모수적 기대최대치(NPEM) 연산방법에 의한 겐타마이신의 모집단 약물동태학

  • Received : 2011.01.23
  • Accepted : 2011.05.03
  • Published : 2011.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Population pharmacokinetics for gentamicin were compared with 20 Korean patients (14 male and 6 female) and 25 Caucasian appendicitis patients (16 male and 9 female). Two to six blood specimens were collected from all patients at the following times : just before a regularly scheduled infusion and at 0.5 hour after the end of a 0.5 hour infusion. Nonparametric expected maximum(NPEM) algorithm for population modeling was used. The estimated parameters were the elimination rate constant(K), the slope(KS) of the relationship between K versus creatinine clearance(Ccr), the apparent volume of distribution (V), the slope(VS) of the relationship between V versus weight, gentamicin clearance(CL) and the slope(CS) of the relationship between CL versus Ccr and the V. The output includes two marginal probability density function(PDF), means, medians, modes, variance, skewness, kurtosis, and CV%. The mean K(KS) were$0.402{\pm}0.129hr^{-1}$ ($0.00486{\pm}0.00197[hr{\cdot}mL/min/1.73m^2]^{-1}$) and $0.425{\pm}0.137hr^{-1}$($0.00432{\pm}0.00168[hr{\cdot}mL/min/1.73m^2]^{-1}$) for Korean and Caucasian populations, respectively. The mean V(VS) were not different at $14.3{\pm}3.69L$($0.241{\pm}0.0511L/kg$) and $15.8{\pm}4.81L$($0.236{\pm}0.0531L/kg$) for Korean and Caucasian populations, respectively (P>0.2). The mean CL(CS) were $5.68{\pm}1.69L/hr$ ($0.0714{\pm}0.0222L/kg[hr{\cdot}mL/min/1.73m^2]$) and $6.29{\pm}1.84L/hr$ ($0.0629{\pm}0.0189L/kg[hr{\cdot}mL/min/1.73m^2]$) for Korean and Caucasian populations, respectively. There are no differences in gentamicin pharmacokinetics between Korean and Caucasian appendicitis patients.

Keywords

References

  1. Sheiner BB, Beal S, Rosenberg B, et al., Forecasting individual pharmacokinetics. Clin Pharmac Ther 1979; 31: 294-9.
  2. Hurst A, Yoshinaga M, Mitani G, et al., Application of a bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother 1990; 34: 1165-71. https://doi.org/10.1128/AAC.34.6.1165
  3. Touw DJ, Proost JH, Stevens R, et al., Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus. Pharm World Sci 2001; 23: 200-8. https://doi.org/10.1023/A:1012490704731
  4. Nielsen EI, Sandström M, Honoré PH, et al., Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet 2009; 48: 253-9. https://doi.org/10.2165/00003088-200948040-00003
  5. Seaton C, Ignas J, Muchohi S, et al., Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition. J Antimicrob Chemother 2007; 59: 681-90. https://doi.org/10.1093/jac/dkl561
  6. García B, Barcia E, Perez F, et al., Population pharmacokinetics of gentamicin in premature newborns. J Antimicrob Chemother 2006; 58: 372-81. https://doi.org/10.1093/jac/dkl244
  7. Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents 2004; 23: 291-8. https://doi.org/10.1016/j.ijantimicag.2003.07.010
  8. Treluyer JM, Merlé Y, Tonnelier S, et al., Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother 2002; 46: 1381-8. https://doi.org/10.1128/AAC.46.5.1381-1387.2002
  9. Biggeri A, Marchi M, Lagazio C, et al., Non-parametric maximum likelihood estimators for disease mapping. Stat Med 2000; 15: 2539-46.
  10. Bustad A, Terziivanov D, Leary R, et al., Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006; 45: 365- 71. https://doi.org/10.2165/00003088-200645040-00003
  11. Stolk LM, Degraeuwe PL, Nieman FH, et al., Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit 2002; 24: 527-33. https://doi.org/10.1097/00007691-200208000-00011
  12. Rougier F, Claude D, Maurin M, et al., Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother 2003; 47: 1010-18. https://doi.org/10.1128/AAC.47.3.1010-1016.2003
  13. Garrison MW, Zaske DE, Rotschafer JC. Aminoglycosides: another perspective. Ann Pharmacother 1990; 24: 267-73.
  14. Burm JP. The influence of weight with assay error on gentamicin pharmacokinetics using the Bayesian and nonlinear least square regression analysis in appendicitis patients. Biopharm. Drug Dispos 2005; 26: 189-95. https://doi.org/10.1002/bdd.450
  15. Jelliffe RW, D'Argenio DZ, Schumitzky A, et al., The USC*PACK PC programs for planning, monitoring and adjusting drug dosage regimens. Proceedings of the twenty-third annual meeting of the Association for the Advancement of Medical Instrumentation. Washington, DC, May 13, 1988.
  16. Press SJ. Bayesian statistics: Principles, models, and application. John Wiley & Sons, Inc., 1989; 175.
  17. Jelliffe RW, Schumitzky A. User manual for the nonparametric EM program for population pharmacokinetic modeling version 1. University of Southern California, School of Medicine, Los Angeles, Calfornia 1989.
  18. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients. J Pharmacokinet Biopharm 1976; 4: 183-8. https://doi.org/10.1007/BF01086153
  19. Vercaigne LM, Ariano RE, Zacharias JM. Bayesian pharmacokinetics of gentamicin in a haemodialysis population. Clin Pharmacokinet 2004; 43: 205-10. https://doi.org/10.2165/00003088-200443030-00004
  20. Jelliffe RW, Iglesias T, Hurst A, et al., Individualizing gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring stategies. Clin Pharmacokinet 1991; 21: 461-8. https://doi.org/10.2165/00003088-199121060-00006
  21. Erdmann SM, Rodvold KA, Pryka RD. An updated comparison of drug dosing methods. Part III: amionglycoside antibiotics. Clin Pharmacokinet 1991; 20: 374-9. https://doi.org/10.2165/00003088-199120050-00003
  22. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22: 447-13. https://doi.org/10.2165/00003088-199222060-00004
  23. Jelliffe RW, Schumitzky A, Van Guilder M. Nonpharmacokinetic factors affecting aminoglycoside therapeutic precision: A simulation study. Drug Invest 1992; 4: 20-7. https://doi.org/10.1007/BF03258374
  24. Antal EJ, Grasela TH, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part III: prospective data collection versus retrospective data assembly. Clin Pharmacol Ther 1989; 46: 552-8. https://doi.org/10.1038/clpt.1989.185
  25. Gan SH, Ismail R, Wan Adnan WA, et al., Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. J Clin Pharm Ther 2004; 29: 455- 60. https://doi.org/10.1111/j.1365-2710.2004.00590.x
  26. Beal S. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 1984; 16: 173-9.
  27. Beal S. Asymptotic properties of optimization estimates for the independent net identically distributed case with application to extended least-squares estimate. Technical report of the Division of Clinical Pharmacology. University of Califormia, San Francisco 1984.
  28. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986; 73: 645-10. https://doi.org/10.1093/biomet/73.3.645
  29. Mallet A, Mentre F, Steimer JL, et al., Nonparametric maxmum likelihood estimation for population pharmacokinetics with application to cyclosporine. J Pharmacokinet Biopharm 1988; 16: 311-8. https://doi.org/10.1007/BF01062140
  30. Dodge WF, Jelliffe RW, Richardson CJ, et al., Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clin Pharmacol Ther 1991; 50: 25-30. https://doi.org/10.1038/clpt.1991.100
  31. Bond WS. Ethnicity and psychotropic drugs. Clin Pharm 1991; 10: 467-72.
  32. Wood A, Zhou H. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350-6. https://doi.org/10.2165/00003088-199120050-00002
  33. Jhee SS, Burm JP, Gill MA. Comparison of aminoglycoside pharmacokinetics in asian hispanic and caucasian patient using population pharmacokinetic methods. Antimicrob Agents Chemother 1994; 38: 2073-8. https://doi.org/10.1128/AAC.38.9.2073
  34. Botha JH, du Preez MJ, Adhikari M. Population pharmacokinetics of gentamicin in South African newborns. Eur J Clin Pharmacol 2003; 59: 755-60. https://doi.org/10.1007/s00228-003-0663-6